Akorn (AKRX +2%) makes new 52-week highs after Deutsche reiterates a Buy on the drug developer. The firm is lifting its estimates following Akorn's acquisition of 3 injectable products, and claims the company's pipeline, expansion efforts, and growth opportunities leave it well-positioned to deliver 30%+ EPS growth over the next 3 years. It also believes Akorn is a potential takeover candidate.